Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
New Clinical Data at ACC09 Show the CYPHER(R) Sirolimus-eluting Coronary Stent Outperformed TAXUS(R) LIBERTE(R) and ENDEAVOR(R) Stents in Key Outcome Measures Apr 9, 2009 |
19.4 KB |
|
|
BRIDGEWATER, N.J., Apr 09, 2009 (BUSINESS WIRE) -- As this year's American College of Cardiology Annual Scientific Sessions conclude, interventional cardiologists from around the world are returning to their catheterization labs with new information from clinical trials about how the CYPHER(R) Sirolimus-eluti... |
|||
|
Health Canada Approves PREZISTA* Once Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1 Apr 7, 2009 |
10.3 KB |
|
|
TORONTO, April 7 /CNW/ - Tibotec, a division of Janssen-Ortho Inc., announced today that Health Canada has approved PREZISTA* (darunavir) for use in treatment-naive adults (those who have never taken HIV medication before), dosed once daily in combination with other antiretroviral agents. The new indication for PREZISTA includes a new tablet str... |
|||
|
Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results Apr 7, 2009 |
6.1 KB |
|
|
NEW BRUNSWICK, N.J., April 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host a conference call for financial analysts at 8:30 a.m. (Eastern Time) on Tuesday, April 14, 2009, to review first-quarter results. Dominic Caruso, Vice President, Finance and Chief Financial Officer, and Louise Mehrotra, Vice President, ... |
|||
|
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder Apr 1, 2009 |
61.7 KB |
|
|
San Diego, Calif. (April 1, 2009) - Patients with schizoaffective disorder who received paliperidone extended release tablets (paliperidone ER) for six weeks showed significant improvement in a broad range of schizoaffective symptoms, according to a new study presented today at the 12th International Congress on Schizophrenia Re... |
|||
|
District Court Decision Received in CONCERTA® Patent Case Mar 31, 2009 |
8.9 KB |
|
|
Titusville, N.J. (March 31, 2009)- The U.S. District Court for the District of Delaware has rendered a decision in the patent litigation between Alza Corporation, McNeil-PPC, Inc. and Andrx Pharmaceuticals LLC. McNeil Pediatrics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., which markets CONCERTA® (methylphenidate HCI) Extended-Re... |
|||
|
U.S. FDA Approves New THERAKOS™ CELLEX™ Photopheresis System Mar 23, 2009 |
9.0 KB |
|
|
EXTON, Pa., March 23 /PRNewswire/ -- Therakos, Inc., a pioneer in immune cell therapy, today announced the U.S. Food and Drug Administration (FDA) approval of the THERAKOS™ CELLEX™ Photopheresis System for the palliative (reducing the severity of symptoms) treatment of the skin manifestations (appearance) of cutaneous T-cell lymphoma (... |
|||
|
FDA Advisory Committee Finds Favorable Risk-Benefit Profile for Oral Anticoagulant Rivaroxaban for Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism after Hip or Knee Replacement Surgery Mar 19, 2009 |
10.6 KB |
|
|
Raritan, NJ (March 19, 2009)-Ortho-McNeil, announced today that the U.S. Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee has determined that rivaroxaban, a novel, investigational, oral anticoagulant, has a favorable risk-benefit profile for the prophylaxis of deep vein thrombosis (DVT) and pulmonar... |
|||
|
Cordis Corporation Announces Head-to-Head Randomized Clinical Trial Comparing the NEVO(TM) Sirolimus-Eluting Coronary Stent to the XIENCE(TM) Stent Mar 16, 2009 |
17.0 KB |
|
|
BRIDGEWATER, N.J., Mar 16, 2009 (BUSINESS WIRE) -- Cordis Corporation, a worldwide leader in the field of interventional cardiology, announced plans today to launch a global, head-to-head, randomized clinical trial called NEVO II which will compare the NEVO(TM) Sirolimus-eluting Coronary Stent to the XIENCE V(TM) ... |
|||
|
Johnson & Johnson to Provide Webcast Presentation of Tapentadol Extended Release (ER) Phase 3 Clinical Data Presented at World Institute of Pain 5th Annual World Congress Mar 12, 2009 |
6.4 KB |
|
|
NEW BRUNSWICK, N.J., March 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for financial analysts on Sunday, March 15 at 10:00 a.m. (Eastern Time) to coincide with the World Institute of Pain 5th World Congress (WIP) in New York City. Phase 3 clinical data on investigatio... |
|||
|
Johnson & Johnson to Participate in the 29th Annual Cowen & Company Health Care Conference Mar 10, 2009 |
5.7 KB |
|
|
NEW BRUNSWICK, N.J., March 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will participate in the 29th Annual Cowen & Company Health Care Conference on Monday, March 16th at the Boston Marriott Copley Place Hotel in Boston, Massachusetts. Dominic J. Caruso, Vice President, Finance and Chief Financial Officer, will rep... |
|||
|
CYPHER(R) Sirolimus-eluting Coronary Stent Demonstrates Sustained Benefits Compared to Bare-Metal Stents in Six-Year Randomized Clinical Trial Mar 5, 2009 |
13.4 KB |
|
|
WASHINGTON, Mar 05, 2009 (BUSINESS WIRE) -- In the first six-year follow-up of a pivotal study of any drug-eluting stent, the clinical benefits of the CYPHER(R) Sirolimus-eluting Coronary Stent compared to a bare-metal stent (BMS) were sustained according to data presented here at the Cardiovascular Revascularization... |
|||
|
CHMP delays European Commission decision process to approve ZEVTERA ™ Feb 24, 2009 |
9.9 KB |
|
|
Beerse, Belgium, 23 February 2009 - Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on ZEVTERATM (ceftobiprole medocaril) pending completion of a Good Clinical Practice (GCP) inspection. ZEVT... |
|||
|
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder Feb 10, 2009 |
11.8 KB |
|
|
TITUSVILLE, N.J., Feb 10, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that the Food and Drug Administration (FDA) has asked for additional information regarding the company's supplemental New Drug Application (sNDA) for RISPERDAL(R) CONSTA(R) (risper... |
|||
|
Priligy™ (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden Feb 10, 2009 |
11.2 KB |
|
|
Beerse, Belgium, 10 February, 2009 - Janssen-Cilag EMEA, a division of Janssen Pharmaceutica N. V., announced today that Priligy™ (dapoxetine) has received marketing authorisation in Finland and Sweden for the on-demand treatment of premature ejaculation (PE) in men 18-64 years of age. These approvals follow the po... |
|||
|
FDA Grants Marketing Approval to NAVISTAR(R) THERMOCOOL(R) Catheter for Atrial Fibrillation Feb 6, 2009 |
20.9 KB |
|
|
DIAMOND BAR, Calif., Feb 06, 2009 (BUSINESS WIRE) -- Biosense Webster, Inc., a Johnson & Johnson company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval to the NAVISTAR(R) THERMOCOOL(R) Catheter for the treatment of drug refractory recurrent symptomatic ... |
|||
|
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R) Feb 6, 2009 |
12.9 KB |
|
|
TITUSVILLE, N.J., Feb 06, 2009 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the company has submitted multiple applications to the U.S. Food and Drug Administration (FDA) which, if approved, would broaden treatment options for patients diagnosed with schizophre... |
|||
|
Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for INTELENCE™ (etravirine) Feb 5, 2009 |
12.0 KB |
|
|
BRIDGEWATER, N.J., Feb. 5 /PRNewswire/ -- Tibotec, Inc. today announced it has submitted an application to the U.S. Food and Drug Administration (FDA) seeking traditional approval for INTELENCE™ (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). The application for traditional a... |
|||
|
Once-Daily Prezista® (darunavir) for Treatment-Naïve Adults with HIV-1 Receives Approval in the European Union as Part of Combination Therapy Feb 3, 2009 |
61.3 KB |
|
|
Cork, Ireland: 3rd February 2009 - Tibotec Pharmaceuticals announced today that the European Commission approved once-daily dosing of 800 mg PREZISTA® (darunavir), a protease inhibitor, with low-dose ritonavir as part of combination therapy in treatment-naïve adults (those who have never taken HIV medication before... |
|||
|
Health Canada Clears New Therakos™ Cellex™ Photopheresis System Jan 28, 2009 |
9.0 KB |
|
|
Exton, PA (January 28, 2009) - Therakos, Inc., a pioneer in photopheresis therapy for more than 20 years, today announced that Health Canada has cleared the THERAKOS™CELLEX™Photopheresis System for the palliative (reducing the severity of symptoms) treatment of the skin manifestations (appearance) of cutaneous T... |
|||
|
Johnson & Johnson Completes Acquisition of Mentor Corporation Jan 23, 2009 |
6.0 KB |
|
|
NEW BRUNSWICK, N.J., Jan 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced the completion of its previously announced acquisition of Mentor Corporation (NYSE: MNT), a leading supplier of medical products for the global aesthetic market. Mentor is expected to operate as a stand-alone business un... |
|||
= add release to Briefcase
